Updated from 1:53 p.m.
were easily among the best-performing health and pharmaceutical stocks Friday, rising 114% after the company said its lung cancer vaccine showed promising results in midtrial testing.
The biotech company said that its BLP25 Liposome vaccine, which is being used by a subset of patients receiving treatment for late-stage non-small cell lung cancer, showed that after 23 months the median survival rate had not yet been reached following the enrollment of the last patient into the trial. "We believe that the results to date are very exciting, and we look forward to presenting the data," Biomira said. The company and its partner, Merck KGaA, plan to discuss a phase III multinational registration trial with regulatory authorities in 2005. Shares traded up $1.75 to $3.28.
fell 8.2% after the company warned that implants of its Destination Therapy product in the fourth quarter would be flat with levels from the first three quarters of the year. Thoratec said that strong performance in other areas of its business was helping to mitigate the Destination trend. In June, the company warned Wall Street that its full-year earnings and sales would miss expectations because of weaker-than-expected sales of its Destination implants. Shares traded down 88 cents to $9.83.
rose 9.4% after the company received a $10 million licensing payment from
( SGP). In addition, Schering-Plough will purchase ViroPharma's existing inventory of bulk drug substance for up to an additional $6 million. What's more, ViroPharma is eligible to receive up to an additional $65 million in milestone payments, contingent upon reaching certain regulatory and commercial events. ViroPharma licensed pleconaril to Schering-Plough for the treatment of the common cold in the U.S. and Canada. Shares traded up 26 cents to $3.03.
Other health care volume movers included
, down 57 cents to $27.89;
, up 8 cents to $28.68;
, down 93 cents to $62.01;
, down 22 cents to $5.99; and
( GORX), down $1.91 to $5.46.